DMSG - Deutsche Multiple Sklerose Gesellschaft Bundesverband e.V.

DMSG ExpertenforenPathogenese der MS - wie entsteht die Erkrankung? · frage zu anderen mitteln



Hinweis: Diese Diskussion wurde geschlossen. Auf Beiträge kann nicht mehr geantwortet werden.

Verfasser Beitrag
(hans) 13.08.2005, 14:40
sehr geehrter prof.gold,
auch wenn es in diesem forum nichthinein gehört, habe ich dénnoch eine frage- würden sie ldn empfehlen
man liest ja soviel darüber
danke für die antwort
hans
(Anonym) 13.08.2005, 14:59
Diese Frage wurde hier schon mal gestellt.Sie gehört nicht zum Thema dieses Forums und wird nicht beantwortet.Siehe weiter unten.
Experte r.gold 13.08.2005, 17:49
um es ganz neutral zu halten: es gibt eine sehr gute stellungnahme der amerik. MS gesellschaft zu LDN

www.nmss.org..und dann Stichwort LDN
(Dr.Fuhrmann http://naltrexoneforum.thit.de) 14.08.2005, 00:21
Die Stellungsnahme im Volltext,Prof.Gold meinte natürlich die ablehnende erste Stellungsnahme,die auch die DMSG übernahm und bisher nicht revidiert hat,daher nehme ich an er meint diese.Unten die neuere revidierte Stellungsnahme.Wobei​ man die Forderung nach Studien zynisch sehen kann,da man die geringen Möglichkeiten mit LDN Geld zu verdienen kennt.

Low Dose Naltrexone Update

April 2005—We have received a number of inquiries about the use of low dose naltrexone (LDN) as a treatment for multiple sclerosis. To date, there are no published data from controlled clinical trials of LDN in MS. Further study is needed to determine the safety and efficacy of LDN as a treatment for people with MS.

Naltrexone is an opioid antagonist that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of addictions to opioids and alcohol. At significantly lower doses, it has been prescribed as a treatment for a variety of diseases, including various types of cancers, HIV/AIDS, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), emphysema, as well as MS and other autoimmune diseases. Although there is a trial ongoing in Crohn's disease, no data have yet been published in Crohn's or any of these other diseases.

In a recent article by Y.P. Agrawal, MD, PhD, (Med Hypotheses. 2005;64(4):721-4), Dr. Agrawal proposed that LDN reduces disease activity in MS by reducing the destruction of oligodendrocytes, the cells that manufacture myelin. He urged that clinical trials be conducted as soon as possible to determine if the proposed mechanism of action is a safe and effective treatment for MS.

We look forward to seeing published results from the clinical trial of LDN in Crohn's disease and hope that research studies will be conducted in EAE (the animal model of MS) and in MS. As stated on the National MS Society Web site, the Society is open to considering any high quality and relevant research protocol. Any agent that has the potential to safely and effectively treat MS is of interest to the Society. We encourage those researchers and clinicians who believe there are significant benefits to LDN for people with MS to propose and undertake the studies that are required by the dictates of good scientific investigation and also required by regulatory authorities.


Research and Clinical Programs Department
in collaboration with
Allen Bowling, MD, PhD
Rocky Mountain MS Center